Kevin Feeley Sells 388 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

Key Points

• Kevin Feeley, CFO of GeneDx Holdings Corp., sold 388 shares of the company's stock at an average price of $105.31, totaling approximately $40,860.28, which lowered his ownership in the company by 9.36%.
• GeneDx reported a strong quarterly earnings result with an EPS of $0.50, exceeding the consensus estimate of $0.10, and generated revenue of $102.69 million, surpassing expectations of $86.00 million.
• Several institutional investors have significantly increased their stakes in GeneDx, with William Blair Investment Management LLC boosting its position by 37.2%, now holding shares worth approximately $150.6 million.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 388 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $105.31, for a total transaction of $40,860.28. Following the completion of the sale, the chief financial officer directly owned 3,757 shares in the company, valued at approximately $395,649.67. The trade was a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, July 9th, Kevin Feeley sold 5,278 shares of GeneDx stock. The stock was sold at an average price of $93.00, for a total transaction of $490,854.00.
• On Tuesday, July 1st, Kevin Feeley sold 1,344 shares of GeneDx stock. The stock was sold at an average price of $91.12, for a total transaction of $122,465.28.
• On Monday, June 2nd, Kevin Feeley sold 370 shares of GeneDx stock. The stock was sold at an average price of $71.26, for a total transaction of $26,366.20.

GeneDx Stock Down 1.5%

Shares of WGS traded down $1.56 during trading hours on Thursday, reaching $101.95. The company's stock had a trading volume of 1,175,567 shares, compared to its average volume of 1,095,327. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of 2,039.00 and a beta of 2.01. GeneDx Holdings Corp. has a 1-year low of $25.32 and a 1-year high of $117.75. The company has a quick ratio of 3.07, a current ratio of 3.25 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average of $78.73 and a two-hundred day moving average of $82.64.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.10 by $0.40. The business had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx had a return on equity of 17.24% and a net margin of 0.39%. As a group, research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Several large investors have recently made changes to their positions in WGS. William Blair Investment Management LLC boosted its position in GeneDx by 37.2% during the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company's stock worth $150,595,000 after purchasing an additional 442,414 shares during the period. Vanguard Group Inc. boosted its position in GeneDx by 2.5% during the first quarter. Vanguard Group Inc. now owns 1,031,326 shares of the company's stock worth $91,339,000 after purchasing an additional 25,116 shares during the period. Summit Partners Public Asset Management LLC boosted its position in shares of GeneDx by 336.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company's stock valued at $58,073,000 after acquiring an additional 582,619 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of GeneDx in the fourth quarter valued at approximately $48,458,000. Finally, Fred Alger Management LLC boosted its position in shares of GeneDx by 2.0% in the first quarter. Fred Alger Management LLC now owns 557,018 shares of the company's stock valued at $49,332,000 after acquiring an additional 10,964 shares during the period. Institutional investors own 61.72% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on WGS shares. Jefferies Financial Group upgraded shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a research note on Friday, May 9th. Wells Fargo & Company lifted their price target on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Piper Sandler began coverage on shares of GeneDx in a research note on Wednesday, July 9th. They issued an "overweight" rating and a $110.00 price target for the company. TD Securities lowered their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Wall Street Zen lowered shares of GeneDx from a "buy" rating to a "hold" rating in a research note on Sunday, July 13th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, GeneDx currently has an average rating of "Moderate Buy" and a consensus target price of $94.22.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.